Pharmaceutical Technology Europe, Sep 1, 2010 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Sep 1, 2010
Special Feature
How A CMO Can Compete In An Increasingly Competitive Market
By Dianne Sharp
In an increasingly competitive landscape, outsourcing providers are under mounting pressure to get their name out there and secure new and repeat business.
The Effect Of The Financial Crisis On Outsourcing
By Jagdish Dalal
The economic crisis has affected outsourcing providers in several ways.
How Responsible Should The Sponsor Be For The Outsourcing Provider's Success?
By John Avellanet
When assessing the competencies of an outsourcing service provider, sponsor companies must pay a great deal of attention to the cGMP compliance level of the provider.
How To Identify The Right Outsourcing Partner In Asia–Pacific
By Dr Frank Floether
How to find the right partner in Asia–Pacific is a very complex question and there is no uniform answer.
Outsourcing: The Indian Perspective
By Marcel Velterop
India has evolved from a low-cost region to an area with extensive technical capability and high quality standards.
Continuous Processing: Is The Pharma Industry Finally Coming Round To The Idea?
By Fedra Pavlou , Kevin Nepveux , Kris Schoeters , Andreas Weiler , Shawn Whitfield
Industry experts discuss the merits of continuous processing technology and explain why pharma manufacturers should realize the benefits these technologies offer.
The Biosimilars Market Today And Tomorrow
By Alan Sheppard
Last year, the global market for biological products exceeded $125 billion, accounting for 17% of the total market for pharma/biopharma products.
A SWOT Analysis Of The Biosimilars Market
By Anjan Selz
A Strengths, Weaknesses, Opportunities and Threats analysis of the biosimilars market is given.
Clinical And Cost Considerations Of Developing A Biosimilar
By Keith Watson , Cecil Nick , Bruce Babbitt
Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.
Launching And Commercializing Biosimilars
By Paul Greenland
Many hurdles lie between a biosimilar and success on the market. In particular, there are three main questions that companies will be asking themselves.
Biosimilars: Perception, cost And The Impact On Biotech Innovation
By Ameet Malik
In light of the impressive size and predicted growth of the market, there has been a rising interest in the development of biosimilars.
Drug Delivery
Understanding The Requirements For Effective Nasal Drug Delivery
By Paul Kippax , Julie Suman , Gerallt Williams
One particularly crucial parameter for nasal sprays is the size of the droplets produced during actuation, which can potentially impact bioavailability.
Handling HPAPIs
By Marc Venet
The manufacture of high potency active pharmaceutical ingredients (HPAPIs) is on the rise with R&D projects showing a continuing interest in these products.
Use Of RFID Asset Management Systems For Monitoring Analytical Instrumentation
By Ralph M. Dioguardi , Paul Smith
Utilizing integrated active radio frequency identification (RFID) and real-time asset management systems can yield commercial and compliance benefits.
Industry Insider
Behind The Scenes Of Pharma Mergers And Acquisitions
By Nathan Jessop
Despite the poor economic climate, large-scale mergers and acquisitions in the pharmaceutical industry struck back with a vengeance in 2009.
Pharma struggling with social media; Opportunities in the OTC market
Editor's Comment
Approach social media with caution?
By Fedra Pavlou
No one can deny the power of social media; it has revolutionised communication and empowered consumers, creating a medium that allows the free flow of information with no authority to control it.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here